Management of drug-induced liver injury associated with anti-cancer therapy
Frontiers in Physiology · 27.03.2025 · 16
DOI: 10.3389/fphys.2025.1541020 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Physiology, online erschienen am 27.03.2025. Verfasst von Bruno Vincenzi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Policlinico Universitario Campus Bio-Medico, Rome, Italy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Abbott Laboratories.
Abstract (Originalsprache)
Drug-induced liver injury (DILI) is a leading cause of drug withdrawal, a particular cause for concern among patients receiving anti-cancer treatment. This review summarizes the available evidence on the efficacy of hepatoprotective drugs in normalizing liver enzyme abnormalities among patients with DILI due to treatment with anti-cancer therapies. Across relevant publications, the effects of several compounds on anti-cancer therapy-induced DILI were assessed. Treatment with hepatoprotective agents which is usually initiated after DILI has been detected and involves cessation of causative anti-cancer therapy, has demonstrated improvements in liver enzyme elevation. However, prophylactic treatment with two agents in particular, ademetionine and bicyclol have shown hepatoprotective effects that enabled patients to continue with their anti-cancer therapy with a reduced subsequently reduced risk of hepatotoxicity. While these publications show some evidence for the benefits of hepatoprotective agents among patients with DILI due to anti-cancer therapy, more research is needed to fully determine the effects of hepatoprotective drugs in resolving DILI signs and symptoms among patients receiving treatment for cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Oncology, Policlinico Universitario Campus Bio-Medico, Rome, Italy.
- Division of Gastroenterology and Hepatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, NHC Key Laboratory of Digestive Diseases, Shanghai Research Center of Fatty Liver Disease, Shanghai, China.
- Servicios de Aparato Digestivo, Instituto de Investigación Biomédica de Málaga IBIMA_Plataforma Bionand, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain.
- CIBERehd, Madrid, Spain.
- Abbott Products Operations AG, Allschwil, Switzerland.
- CIC bioGUNE, CIBERehd, Parque Tecnológico de Bizkaia, Derio, Spain Parque Tecnológico de Bizkaia, Derio, Spain.
Förderung
- Abbott Laboratories
Zitieren
APA
Vincenzi, B., Yimin, M., Andrade, R. J., Morales Castillo, M., Akhundova-Unadkat, G., & Mato, J. M. (2025). Management of drug-induced liver injury associated with anti-cancer therapy. Frontiers in Physiology, 16. https://doi.org/10.3389/fphys.2025.1541020
Vancouver
Vincenzi B, Yimin M, Andrade RJ, Morales Castillo M, Akhundova-Unadkat G, Mato JM. Management of drug-induced liver injury associated with anti-cancer therapy. Frontiers in Physiology. 2025;16. doi:10.3389/fphys.2025.1541020
BibTeX
@article{Vincenzi2025,
author = {Vincenzi, Bruno and Yimin, Mao and Andrade, Raúl J and Morales Castillo, Mauricio and Akhundova-Unadkat, Gamar and Mato, José M},
title = {Management of drug-induced liver injury associated with anti-cancer therapy},
journal = {Frontiers in Physiology},
year = {2025},
volume = {16},
doi = {10.3389/fphys.2025.1541020}
}
EUVIMED